ADVFN Logo ADVFN

We could not find any results for:
Make sure your spelling is correct or try broadening your search.

Trending Now

Toplists

It looks like you aren't logged in.
Click the button below to log in and view your recent history.

Hot Features

Registration Strip Icon for default Register for Free to get streaming real-time quotes, interactive charts, live options flow, and more.

PBX Probiotix Health Plc

5.75
0.00 (0.00%)
06:57:34 - Realtime Data
Share Name Share Symbol Market Type Share ISIN Share Description
Probiotix Health Plc AQSE:PBX Aquis Stock Exchange Ordinary Share GB00BLNBFR86
  Price Change % Change Share Price Bid Price Offer Price High Price Low Price Open Price Shares Traded Last Trade
  0.00 0.00% 5.75 5.00 6.50 5.75 5.75 5.75 0.00 06:57:34
Industry Sector Turnover Profit EPS - Basic PE Ratio Market Cap
0 0 N/A 0

Probiotix Health PLC Holding(s) in Company

27/09/2024 11:23am

RNS Regulatory News


RNS Number : 0439G
Probiotix Health PLC
27 September 2024
 

27 September 2024

                                                                                                

ProBiotix Health plc

("ProBiotix" or the "Company" or, together with its subsidiary, the "Group")

 

Holding in the Company

 

ProBiotix Health plc (AQSE: PBX), the life sciences business developing probiotics to support cardiometabolic health, announces that it has received a TR-1 Form, which is reproduced without amendment below.

 

The TR1 Form reflects transfers made from the holding of Holdingselskabet af 29. Juni 2010 Aps, the family office vehicle of Frederik Bruhn-Petersen, to members of Mr Bruhn-Petersen's family.

 

For further information, please contact:

 

 

ProBiotix Health plc

https://probiotixhealth-ir.com/

Steen Andersen, Chief Executive Officer

 



Peterhouse Capital Limited

(Aquis Corporate Adviser and Broker)

Tel: 020 7469 0930

Mark Anwyl

 


Walbrook PR Ltd

Anna Dunphy

 

probiotix@walbrookpr.com

Mob: 07876 741 001

 

NOTIFICATION OF MAJOR HOLDINGS (to be sent to the relevant issuer and to the FCA in Microsoft Word format if possible)


1a. Identity of the issuer or the underlying issuer of existing shares to which voting rights are attached:

PROBIOTIX  HEALTH PLC

1b. Please indicate if the issuer is a non-UK issuer  (please mark with an "X" if appropriate)

Non-UK issuer


2. Reason for the notification (please mark the appropriate box or boxes with an "X")

An acquisition or disposal of voting rights

X

An acquisition or disposal of financial instruments


An event changing the breakdown of voting rights


Other (please specify):


3. Details of person subject to the notification obligation

Name

Holdingselskabet af 29. juni 2010 ApS

City and country of registered office (if applicable)

COPENHAGEN, DENMARK

4. Full name of shareholder(s) (if different from 3.)

Name


City and country of registered office (if applicable)


5. Date on which the threshold was crossed or reached:

25/09/2024

6. Date on which issuer notified (DD/MM/YYYY):

26/09/2024

7. Total positions of person(s) subject to the notification obligation


% of voting rights attached to shares (total of 8. A)

% of voting rights through financial instruments
(total of 8.B 1 + 8.B 2)

Total of both in % (8.A + 8.B)

Total number of voting rights of

issuer

Resulting situation on the date on which threshold was crossed or reached

20.97%


20.97%

158,166,666

Position of previous notification (if

applicable)

23.08%


23.08%


 

8. Notified details of the resulting situation on the date on which the threshold was crossed or reached

A: Voting rights attached to shares

Class/type of
shares

ISIN code (if possible)

Number of voting rights

% of voting rights

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

Direct

(Art 9 of Directive 2004/109/EC) (DTR5.1)

Indirect

(Art 10 of Directive 2004/109/EC) (DTR5.2.1)

GB00BLNBFR86

33,160,000


20.97%












SUBTOTAL 8. A



 

 

B 1: Financial Instruments according to Art. 13(1)(a) of Directive 2004/109/EC (DTR5.3.1.1 (a))

Type of financial

instrument

Expiration
date

Exercise/
Conversion Period

Number of voting rights that may be acquired if the instrument is

exercised/converted

% of voting rights


















SUBTOTAL 8. B 1



 

 

B 2: Financial Instruments with similar economic effect according to Art. 13(1)(b) of Directive 2004/109/EC (DTR5.3.1.1 (b))

Type of

Financial

instrument

Expiration
date

Exercise/
Conversion

Period

Physical or cash

settlement

Number of voting rights

% of voting rights





















 

SUBTOTAL 8.B.2



 

9. Information in relation to the person subject to the notification obligation (please mark the

applicable box with an "X")

Person subject to the notification obligation is not controlled by any natural person or legal entity and does not control any other undertaking(s) holding directly or indirectly an interest in the (underlying) issuer

X

Full chain of controlled undertakings through which the voting rights and/or the
financial instruments are effectively held starting with the ultimate controlling natural person or legal entity
(please add additional rows as necessary)


Name

% of voting rights if it equals or is higher than the notifiable threshold

% of voting rights through financial

instruments if it equals or is higher than the

notifiable threshold

Total of both if it equals or is higher than the

notifiable threshold





















 

10. In case of proxy voting, please identify:

Name of the proxy holder


The number and % of voting rights held


The date until which the voting rights will be held



11. Additional information


 

Place of completion

Copenhagen, Denmark

Date of completion

26/09/2024

 

 

This information is provided by RNS, the news service of the London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact rns@lseg.com or visit www.rns.com.

RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the London Stock Exchange use the personal data you provide us, please see our Privacy Policy.
 
END
 
 
NEXUBARRSNUKUAR

1 Year Probiotix Health Chart

1 Year Probiotix Health Chart

1 Month Probiotix Health Chart

1 Month Probiotix Health Chart